Microrna (miRNA) Market Size 2024-2028 

The microrna (miRNA) market size is forecast to increase by USD 3.19 billion at a CAGR of 23.31% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of neurological disorders and the immunological status of patients. This market is driven by therapeutic advancements in miRNA therapy, particularly in cancer treatment. Traditional knowledge and target prediction methods are being utilized to identify potential miRNA-based therapeutic strategies. The heterogeneity of miRNA methodologies poses a challenge, but partnerships and collaborations among market players are helping to address this issue. Serum biomarkers are becoming increasingly important in the diagnosis and prognosis of various diseases, and miRNAs are proving to be valuable biomarkers in this regard. Gene expression profiling using miRNAs is a promising area of research, and the potential applications of miRNA therapy in disease treatment are vast. In summary, the miRNA market is witnessing growth due to the increasing need for effective therapeutic strategies for neurological disorders and cancer, and the potential of miRNAs as biomarkers and therapeutic agents.

 Request Free Sample

MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in gene regulation. These molecules have gained significant attention in the field of genomic technologies due to their potential applications in various disease areas, including cancer, cardiovascular diseases, and neurological disorders. miRNAs have emerged as essential noninvasive biomarkers for disease diagnostics. In cancer, miRNAs have been identified as tumor suppressors and oncogenes, making them valuable in disease diagnosis and prognosis. In cardiovascular diseases, miRNAs have shown promise in molecular diagnostics, particularly in the identification of acute kidney injury and atherosclerosis.

In addition, in neurological disorders, miRNAs have been linked to gene regulation and have potential in vaccine development. The use of miRNAs in genomic technologies is expanding, with various instruments, kits, and reagents available for their isolation and purification. These tools enable researchers to obtain high-quality samples for clinical studies, ensuring standardized protocols and accurate results. Precision medicine is a rapidly evolving field, and miRNAs have a significant role to play. They offer noninvasive methods for disease diagnostics and can be used in real-time PCR, next-generation sequencing, microarrays, and liquid biopsies for research purposes. miRNAs have been identified as biomarkers for various chronic disorders and can aid in the development of diagnostic kits for early disease detection.

Also, miRNAs have also shown potential in the field of gene regulation. They can regulate the expression of genes involved in disease development and progression, making them valuable in therapeutic applications. In cancer, miRNAs have been shown to regulate oncogenes, offering potential for the development of targeted therapies. In conclusion, miRNAs are a valuable resource in the field of genomic technologies. Their potential applications in cancer, cardiovascular diseases, and neurological disorders, as well as their role in gene regulation, make them an essential component of research tools and diagnostic kits. The use of miRNAs in noninvasive methods, such as real-time PCR, next-generation sequencing, microarrays, and liquid biopsies, ensures accurate and standardized results, contributing to the advancement of molecular diagnostics and precision medicine.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Consumables
  • Instruments
• End-user
  • Academic and government research institutes
  • Biotechnology and pharmaceutical companies
  • CROs and clinical diagnostic centers
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Type Insights

The consumables segment is estimated to witness significant growth during the forecast period. The miRNA market holds immense potential in the healthcare industry, particularly in the diagnosis and management of chronic disorders, including tumor suppressor miRNAs. Instruments, kits, and reagents play a crucial role in the isolation and purification of miRNAs for disease diagnostics. The consumables segment, comprising whole blood, serum, and plasma, among others, contributes significantly to market growth due to the frequent purchase of a diverse range of consumables for various testing purposes.

Get a glance at the market share of various segments Request Free Sample

The consumables segment was valued at USD 484.70 million in 2018 and showed a gradual increase during the forecast period. End-users, including healthcare facilities, rely on consumables such as plasma and serum for conducting tests and experiments. The demand for a broad range of reagents based on the specific requirements of different applications presents an opportunity for manufacturers to offer an extensive portfolio of consumables to cater to the needs of end-users. The applications of miRNAs extend to various fields, including acute kidney injury and the regulation of oncogenes.

Regional Insights

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

In the realm of Molecular Biology, the miRNA market holds significant importance due to its role in Gene Regulatory Networks and RNA Biology. The North American region leads the global market in this sector, accounting for the largest share. This dominance is primarily attributed to the substantial investment in research and development activities, particularly in the US, for gene therapy. The region's potential is further amplified by the numerous clinical trials underway, primarily in the US, to treat diseases such as cancer, HIV/AIDS, and cardiovascular diseases (CVDs). With cancer being a major health concern in North America, resulting in a significant loss of lives, the region's focus on miRNA research is crucial.

For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, there was an increase of over 24% in new cancer cases compared to the previous year. The therapeutic options offered by miRNAs in treating these diseases make it a promising area for further exploration.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Market Driver

The increasing prevalence of neurological disorders is the key driver of the market. Neurological disorders, such as Alzheimer's disease, epilepsy, stroke, Parkinson's disease, and brain tumors, have seen a substantial rise in prevalence rates globally. Factors contributing to this trend include bacterial and viral infections, genetic predispositions, and weakened immune responses. Individuals with diabetes mellitus, obesity, high blood pressure, hypertension, and smoking addictions are particularly susceptible. According to the Centers for Disease Control and Prevention (CDC), the prevalence of Parkinson's disease increases from 1% to 4% in the aging population between 60 and 80 years old.

Similarly, cancer and cardiovascular diseases pose significant health challenges, affecting millions worldwide. The genomic technologies revolution, including precision medicine, noninvasive biomarkers, and gene regulation, offer promising solutions. Vaccine development and gene therapy are key areas of focus in the fight against these diseases. By harnessing the power of these advancements, we can improve patient outcomes and ultimately save lives. Keywords: neurological disorders, Alzheimer's disease, epilepsy, stroke, Parkinson's disease, brain tumors, diabetes mellitus, obesity, high blood pressure, hypertension, smoking addiction, genomic technologies, precision medicine, noninvasive biomarkers, gene regulation, vaccine development, gene therapy.

Market Trends

The increasing number of partnerships and collaborations of market companies is the upcoming trend in the market. The market is experiencing significant growth due to an increasing number of collaborations and partnerships between companies and end-users, as well as medical technology companies. These strategic alliances aim to enhance distribution networks and expand product offerings. For example, in March 2023, QIAGEN collaborated with Servier, a global pharmaceutical company, to develop companion diagnostics for acute myeloid leukemia (AML) therapy drugs. In a similar vein, Regulus Therapeutics, a miRNA-based biopharmaceutical company, partnered with Harvard's Brigham and Women's Hospital in June 2023, to advance preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of amyotrophic lateral sclerosis.

Moreover, serum biomarkers play a crucial role in target prediction and gene expression analysis in the miRNA market. The immunological status of patients is a critical factor in the therapeutic advancements of miRNA therapy for cancer treatment. miRNA therapy holds immense potential for improving cancer treatment outcomes by modulating gene expression. The therapeutic strategy involves the use of miRNAs to inhibit or enhance the expression of specific target genes.

In conclusion, the miRNA market is witnessing substantial growth due to the increasing number of partnerships and collaborations between companies and end-users, as well as medical technology companies. The potential of miRNA therapy in cancer treatment, driven by target prediction and gene expression analysis, is a significant factor fueling market growth. The use of serum biomarkers and the immunological status of patients are critical factors in the therapeutic strategy, making miRNA therapy a promising area for future advancements in cancer treatment.

Market Challenge

The high heterogeneity of methodologies associated with miRNA is a key challenge affecting market growth. miRNAs, a type of non-coding RNA, have gained significant attention in the biotechnology industry due to their potential diagnostic and therapeutic applications in various diseases, including infectious diseases and cardiovascular diseases (CVDs). Research institutions and academic institutes worldwide are actively conducting studies to explore the use of miRNAs as biological markers for the early detection and diagnosis of diseases. However, the lack of standardization in miRNA quantification methodologies poses a significant challenge for companies in this market. Different research groups employ various matrices, such as age, sex, and ethnicity, which can introduce biological biases. Additionally, technical biases arise from distinct isolation protocols, leading to preferential isolation of exosomes, EVs, platelets, and protein complexes.

However, these differences ultimately affect the relative concentrations of circulating miRNAs, making it difficult to reproduce research results. Clinical trials are underway to evaluate the potential of miRNA diagnostics in the detection and monitoring of diseases. For instance, miRNA diagnostics hold promise in the early detection of acute coronary syndrome, coronary artery disease, heart failure, and other CVDs. However, the heterogeneity of methodologies used for miRNA quantification necessitates the development of standardized protocols to ensure the accuracy and reproducibility of research findings.

In summary, the miRNA market is witnessing significant growth due to the potential of miRNAs in diagnostic and therapeutic applications. The lack of consensus regarding miRNA quantification methodologies poses a challenge for companies. The development of standardized protocols and the use of advanced technologies, such as next-generation sequencing, are essential to address these challenges and ensure the accuracy and reproducibility of research findings.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Miltenyi Biotec B.V. and Co. KG: The company offers miRNA such as GeneChip miRNA 4.0 Array and Flashtag bundle, FlashTag Biotin HSR RNA labeling kits, and mirVana miRNA mimics.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• BioGenex Laboratories Inc.
• Biocompany Laboratorni medicina AS
• GeneCopoeia Inc.
• Genelinx International Inc.
• HEIM BIOTEK
• Illumina Inc.
• InteRNA Technologies B.V.
• Merck KGaA
• NanoString Technologies Inc.
• New England Biolabs Inc.
• OriGene Technologies Inc.
• Perkin Elmer Inc.
• QIAGEN NV
• Quantabio
• Regulus Therapeutics Inc.
• SeqMatic LLC
• Takara Bio Inc.
• TAmiRNA GmbH
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in gene regulation, particularly in the areas of cancer, cardiovascular diseases, and neurological disorders. These molecules have emerged as essential noninvasive biomarkers for disease diagnostics and therapeutic applications. miRNAs are involved in various cellular processes, including gene expression, immunological status, and disease progression. The biotechnology industry is witnessing significant advancements in miRNA research, driven by the potential of miRNAs as therapeutic compounds and diagnostic tools. Genomic technologies, such as RNA profiling, next-generation sequencing, microarrays, and real-time PCR, are being employed for miRNA isolation and purification from various biological samples, including serum, exosomes, and cells.

Further, research institutions and academic institutes are at the forefront of miRNA research, focusing on target prediction, traditional knowledge, and vaccine development. miRNAs have shown promise in the diagnosis and treatment of chronic disorders, including cancer, infectious diseases, and chronic kidney injury. Therapeutic strategies, such as microRNA therapy and oncogene targeting, are being explored for cancer treatment. Clinical trials and clinical studies are underway to evaluate the efficacy of miRNA-based diagnostics and therapeutics. Consumables, instruments, kits, and reagents are being developed to support research and healthcare facilities in the field of miRNA diagnostics and therapeutics. Standardized protocols and high-quality samples are essential for accurate and reliable miRNA analysis.

In summary, miRNAs have also shown potential in the diagnosis and treatment of acute and chronic diseases, such as acute kidney injury and neurological disorders. Molecular diagnostics, translational medicine, and therapeutic options are being explored to leverage the potential of miRNAs in disease management. In summary, miRNAs are playing an increasingly important role in the field of molecular biology and gene regulatory networks, with potential applications in cancer treatment, disease diagnostics, and therapeutic compounds. The miRNA market is expected to grow significantly due to the increasing demand for noninvasive methods and high-quality samples in the healthcare sector.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch